2 results
29/Mar/2022
29/Mar/2022
DOI: 10.31744/einstein_journal/2022AO6453
ABSTRACT Objective To evaluate the therapeutic response (functionality) and its associated factors in patients on biological drugs on the Public Health System for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Methods An open prospective cohort was carried out from 2011 to 2019, in Belo Horizonte (MG). Functionality was assessed using the Health Assessment Questionnaire Disability-Index at baseline, and after 6 and 12 months of follow-up. Factors associated with poor functionality were identified through logistic regression. Results The median […]
Keywords: Arthritis, psoriatic; Arthritis, rheumatoid; Biological products; Effectiveness; Rheumatic diseases; Spondylitis, ankylosing; Unified Health System
31/Jan/2014
31/Jan/2014
DOI: 10.1590/S1679-45082013000400015
OBJECTIVE: To compare the efficacy and the period of use of tocilizumab and infliximab during treatment of rheumatoid arthritis patients. METHODS: The period of use of two biologics with different mechanisms of action were compared in treatment of rheumatoid arthritis patients. RES: ULTS: Both medications showed efficacy, but the period of use with no loss of efficacy was longer in patients receiving tocilizumab when compared to infliximab. CONCLUSION: Tocilizumab maintains a period of use significantly longer as compared with infliximab […]
Keywords: Antibodies, monoclonal; Arthritis, rheumatoid; Biological agents